Human Papillomavirus Quadrivalent Vaccine, Recombinant

Human Papillomavirus Quadrivalent Vaccine, Recombinant, also known as HPV4, is a combination vaccine that protects against four types of Human Papillomavirus (HPV). HPV is a common viral infection that can lead to the development of various cancers, such as cervical, anal, and oropharyngeal cancers. HPV4 is specifically designed to target two high-risk HPV types (16 and 18) responsible for most HPV-related cancers and two low-risk HPV types (6 and 11) responsible for genital warts.
The vaccine is administered as an injection, typically given in a series of two or three doses, depending on the individual’s age and medical history. HPV4 is recommended for both males and females, usually between the ages of 9 and 26, to prevent new HPV infections and reduce the risk of developing HPV-related cancers. The vaccine is most effective when given before exposure to the virus, so administer it before the onset of sexual activity.
HPV4 does not treat existing HPV infections or HPV-related cancers; it only provides protection against future infections. Therefore, regular cervical cancer screenings are still necessary for women, even after receiving the vaccine.